Source: MORNING AG CLIPS, 6/16/21

Amid the FDA’s confirmation it is considering a global reduction on nicotine in cigarettes to non- addictive levels, Demeetra AgBio, Inc., a pre-clinical therapeutics development, agbio, and genetic engineering company, announced that its proprietary gene editing platform, Cas-CLOVER™ can be used to produce harm-reduced tobacco products and therapeutic cannabinoids in a feature with CRISPR Medicine News. The policy the FDA is considering would likely involve a stepwise reduction in nicotine levels in cigarettes until they reach non-addictive levels.

For more of this story, click here.